Effectiveness of anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer (NSCLC) patients

Summary

Project ID: 2021-874/ TRIM 2023 0970 329 000

Principal Investigator: Lara Chayab

Description: The efficacy of ALK inhibitors is established in the clinical trial setting, however, less is known about the effectiveness of ALK inhibitors in practice. The project teams’ overall objective is to evaluate the real-world clinical effectiveness and cost outcomes of ALK inhibitors in patients with ALK positive NSCLC by conducting a population-based retrospective study using the Canadian province of Ontario’s health administrative database hosted at ICES.

PIA Approved: January 25, 2023

Status: In progress